Genes and biomarkers that allow doctors to choose the right therapy for the right patient
...ogene could predict a lack of response to the drug cetuximab in patients with colorectal tumors. For those wit...colleagues studied 114 patients who had been given cetuximab in combination with another drug, irinotecan. According to the researchers, approximately 30 perc...Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer
...patients has found that a combination of the drugs cetuximab (Erbitux) and irinotecan showed a significant impr...uibb and Merck KGaA. "Patients who received both cetuximab and irinotecan experienced longer periods of time spent, on average, without further progression of ...Cetuximab increases survival in advanced colorectal cancer patients, study shows
...omized, multi-center, phase III trial. It compared cetuximab plus best supportive care to best supportive care ...l of the CO.17 study was to evaluate the effect of cetuximab on survival in patients with advanced colorectal cancer who are without other options for treatment ...A genetic 'gang of 4' drives spread of breast cancer
...pes of cancer. The researchers also tested whether cetuximab and celecoxib would work effectively in concert to reduce metastasis in mice. "We found that the combination of these two inhibitory drugs was effective, even though the drugs individually were not very effective," said Massagu. "This really nailed t...AACR Annual Meeting showcases significant developments in understanding and targeting cancers
...ast cancers Late-breaking findings from studies of cetuximab in people with chemotherapy-refractory colorectal cancer Additional briefings will focus on the latest research in patient prognosis, personalized medicine, inflammation, cancer biomarkers, stem cells and cancer diagnosis. With the aim of insp...New cancer therapies at international conference in Amsterdam
...luding, but not limited to, bevacizumab (Avastin), cetuximab (Erbitux) and erlotinib (Tarceva). Updates on these agents and many others in earlier stages of the development pipeline are provided during the TAT symposium. The TAT 2006 program also extensively covers methodological issues in the development of t...Other highlights in the November 16 JNCI
...ntly available therapies. The monoclonal antibody cetuximab (Erbitux), which is approved for the treatment of metastatic colon cancer, inhibits EGFR signaling. However, it must be repeatedly administered to maintain its antitumor effects. Erika Jensen-Jarolim, M.D., Angelika B. Riemer, M.D., Ph.D., and collea...Treatments have same target, different responses for lung cancer patients with genetic mutation
...ssa) is not associated with a response to the drug cetuximab (Erbitux), according to a new study published in t...hers treated seven different NSCLC cell lines with cetuximab or gefitinib, and compared the drugs' effects on cell growth and cell death or apoptosis. They found...Other highlights in the August 17 JNCI
...mentation Some cancer patients being treated with cetuximab (Erbitux) may develop abnormally low blood levels ...loped profound fatigue and hypomagnesemia while on cetuximab therapy, Deborah Schrag, M.D., of Memorial Sloan-Kettering Cancer Center in New York, and colleagues...Two designer drugs hit same lung cancer target, but only one is effective
...utated EGFR molecule. The monoclonal antibody drug cetuximab (Erbitux) had little effect on the mutant signal, evidently because it strikes at a different part of the EGFR molecule. Reporting in the Aug. 17 issue of the Journal of the National Cancer Institute, the researchers say that the divergent results ad...TAT2005 - 3rd International Symposium on Targeted Anticancer Therapies
...cancer therapies, including bevacizumab (Avastin), cetuximab (Erbitux) and bortezomib (Velcade), have already b...sterdam; Thursday, March 3, 15:50-16:20 hours) and cetuximab (Erbitux) (Professor Jos Baselga, Barcelona; Thursday, March 3, 16:20-16:45 hours) and the anti-angi...